Clinical trial · Interventional
The SPARC Trial: Stereotactic Prostate Ablative Radiotherapy Using Cyberknife
Stereotactic Prostate Augmented Radiotherapy With Cyberknife
NCT02145494CI-TRIAL-00014682SPARCunknownPhase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Giving a higher dose of radiation to the dominant tumour nodule within the prostate is hypothesized to improve tumour control. This trial will assess whether this technique, delivered in 5 treatments, can be delivered without increasing side effects.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Prostate Cancer | Malignant Prostate Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Radiotherapy | Radiation | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Treatment
- description
- Radiotherapy
- interventionNames
- Radiation: Radiotherapy
Primary outcomes (1)
- measure
- Acute genitourinary(GU) toxicity
- timeFrame
- Maximal recorded toxicity within the acute toxicity period (up to 12 weeks)
- description
- RTOG scale acute GU toxicity will be measured at baseline, end of treatment, then 2,4 and 12 weeks post treatment. The maximal toxicity during follow up is the primary outcome measure.
Secondary outcomes (4)
- measure
- Acute gastrointestinal (GI) toxicity
- timeFrame
- Within 12 weeks of treatment completion
Eligibility
Eligibility (as posted)
- Sex
- Male
Show eligibility criteria text
Inclusion Criteria: Prostate cancer patients with any of the following: * PSA 20-40 * Gleason grade 4+3 or higher * Stage T3a Exclusion Criteria: * Nodal or metastatic disease * PSA\>40 * Stage T3b or higher
References
Publications (0)
Data not yet available
No reference posted for this study.